Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on Thursday, August 14, 2025, to consider and approve the Unaudited Financial Results for the first quarter ended June 30, 2025 (Q1 FY26). Along with this, the company has closed its trading window for insiders — including directors and designated employees — from June 30, 2025 to August 16, 2025 (both days inclusive), as required under SEBI's Prohibition of Insider Trading Regulations. This is a routine compliance filing ahead of the quarterly earnings announcement.
No direct impact on shareholders as this is a standard regulatory disclosure. Investors should mark August 14, 2025 for the Q1 FY26 earnings announcement, which could influence near-term stock sentiment depending on the results.